Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GLSI
stocks logo

GLSI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.340
-44.26%
--
--
-0.350
+40%
--
--
-0.360
+20%
Estimates Revision
The market is revising No Change the revenue expectations for Greenwich LifeSciences, Inc. (GLSI) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -19.49%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-19.49%
In Past 3 Month
Wall Street analysts forecast GLSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLSI is 45.00 USD with a low forecast of 45.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast GLSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLSI is 45.00 USD with a low forecast of 45.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.800
sliders
Low
45.00
Averages
45.00
High
45.00
Current: 8.800
sliders
Low
45.00
Averages
45.00
High
45.00
Noble Capital
Outperform
initiated
$45
2025-08-20
Reason
Noble Capital
Price Target
$45
2025-08-20
initiated
Outperform
Reason
Noble Capital initiated coverage of Greenwich LifeSciences with an Outperform rating and $45 price target. Greenwich is developing GSLI-100, which has completed four clinical trials that lead to the design of the current Phase 3 Flamingo-01 trial for prevention of breast cancer recurrence in high-risk patients, the analyst tells investors. The firm, which estimates market entry by FY28, sees "large market potential" for GLSI-100.
HC Wainwright & Co.
Yi Chen
Strong Buy
Maintains
$38 → $39
2025-04-21
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$38 → $39
2025-04-21
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$38
2025-02-11
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$38
2025-02-11
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Greenwich Lifesciences Inc (GLSI.O) is -6.20, compared to its 5-year average forward P/E of -29.81. For a more detailed relative valuation and DCF analysis to assess Greenwich Lifesciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-29.81
Current PE
-6.20
Overvalued PE
3.61
Undervalued PE
-63.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 500.34% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 500.34% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

GLSI News & Events

Events Timeline

(ET)
2025-12-03
06:20:00
Greenwich LifeSciences Updates on GLSI-100 Clinical Trial Progress
select
2025-10-09 (ET)
2025-10-09
06:01:33
Greenwich LifeSciences Expands Flamingo-01 Clinical Trial to Include Austria
select
2025-10-02 (ET)
2025-10-02
06:02:01
Greenwich LifeSciences extends Flamingo-01 clinical trial to Belgium
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-03Newsfilter
PinnedGreenwich LifeSciences Screens Over 1,000 Patients for Breast Cancer Immunotherapy Trial
  • Significant Screening Progress: Greenwich LifeSciences has screened over 1,000 patients in the FLAMINGO-01 trial, maintaining a screening rate of approximately 150 patients per quarter, equivalent to 600 patients annually, which reflects high interest from both doctors and patients, thereby accelerating the clinical trial's momentum.
  • Global Expansion Strategy: The company plans to continue enrolling patients in both HLA-A02 and non-HLA-A02 arms, which is expected to enhance the trial's flexibility and efficacy, especially as interest from other countries to join FLAMINGO-01 rises, potentially increasing overall enrollment rates.
  • Clinical Trial Design: The FLAMINGO-01 trial aims to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients, with plans to open up to 150 clinical trial sites globally, ensuring a broader patient base and higher event rates for robust data collection.
  • Data Analysis Potential: The trial is designed to conduct an interim analysis after at least 14 events occur, providing 80% statistical power if the annual event rate in the placebo group is 2.4% or higher, which will offer critical clinical data support for the company's future strategies.
[object Object]
Preview
2.0
12-03Globenewswire
Greenwich LifeSciences Screens Over 1,000 Patients in FLAMINGO-01 Trial
  • Significant Screening Progress: Greenwich LifeSciences has screened over 1,000 patients in the FLAMINGO-01 trial, maintaining a screening rate of approximately 150 patients per quarter, equating to 600 patients annually, which reflects high interest from both doctors and patients, thereby accelerating the study's momentum.
  • Clinical Trial Expansion: The trial is currently active at 140 sites across the US and Europe, with plans to expand to 150 sites globally, not only enhancing recruitment flexibility but also potentially optimizing group sizes and efficacy assessments through multiple interim analyses.
  • Increased Strategic Opportunities: The high screening rate provides the company with various options, including the ability to continue enrolling patients in both HLA-A02 and non-HLA-A02 arms during interim analyses, which could enhance event rates and recruitment speed, thereby strengthening its competitive position in breast cancer immunotherapy.
  • Clear Clinical Objectives: The FLAMINGO-01 trial is designed to detect a hazard ratio of 0.3 for invasive breast cancer-free survival, requiring 28 events, with an interim analysis planned after 14 events, providing 80% statistical power and ensuring the scientific rigor and effectiveness of the study.
[object Object]
Preview
9.5
10-28NASDAQ.COM
Healthcare Rally: Pulmonx, UHS, and X4 Experience After-Hours Gains Following Strategic Announcements

  • Pulmonx Corp. Performance: Pulmonx Corp. saw a significant increase of 33.33% to $2.08 after announcing preliminary Q3 2025 revenue of approximately $21.5 million and leadership changes, including the reappointment of Glen French as President and CEO.

  • Q32 Bio Inc. Gains: Q32 Bio Inc. experienced a 12.5% rise to $3.15 in after-hours trading, although no specific news was reported to explain this increase.

  • Universal Health Services Update: Universal Health Services Inc. climbed 7.41% to $229.90 following its Q3 results and a revised full-year forecast, along with a $1.5 billion increase in its stock repurchase program.

  • X4 Pharmaceuticals Offering: X4 Pharmaceuticals Inc. gained 5.35% to $3.94 after completing a public offering of 52.8 million shares, raising approximately $155.3 million before expenses, increasing total shares outstanding to 79.2 million.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Greenwich Lifesciences Inc (GLSI) stock price today?

The current price of GLSI is 8.8 USD — it has increased 4.64 % in the last trading day.

arrow icon

What is Greenwich Lifesciences Inc (GLSI)'s business?

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. It has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.

arrow icon

What is the price predicton of GLSI Stock?

Wall Street analysts forecast GLSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLSI is 45.00 USD with a low forecast of 45.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Greenwich Lifesciences Inc (GLSI)'s revenue for the last quarter?

Greenwich Lifesciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Greenwich Lifesciences Inc (GLSI)'s earnings per share (EPS) for the last quarter?

Greenwich Lifesciences Inc. EPS for the last quarter amounts to -0.30 USD, increased 50.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Greenwich Lifesciences Inc (GLSI)'s fundamentals?

The market is revising No Change the revenue expectations for Greenwich LifeSciences, Inc. (GLSI) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -19.49%.
arrow icon

How many employees does Greenwich Lifesciences Inc (GLSI). have?

Greenwich Lifesciences Inc (GLSI) has 4 emplpoyees as of December 05 2025.

arrow icon

What is Greenwich Lifesciences Inc (GLSI) market cap?

Today GLSI has the market capitalization of 121.92M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free